# 505845200 01/03/2020

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5892136

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
CHRISTOPHER BECKER	10/24/2019
XIAOLIN LI	10/28/2019
PEICHAO LU	10/30/2019
NAOMI SAMADARA RAJAPAKSA	10/24/2019
DAVID CHARLES TULLY	10/28/2019
XIAOJING MICHAEL WANG	10/29/2019
QIAN ZHAO	10/29/2019

#### **RECEIVING PARTY DATA**

Name:	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.	
Street Address:	250 MASSACHUSETTS AVENUE	
City:	CAMBRIDGE	
State/Country:	MASSACHUSETTS	
Postal Code:	02139	

#### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16569107

### **CORRESPONDENCE DATA**

**Fax Number:** (919)536-6201

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 919.536.6200

Email: lillian.glenn@btlaw.com
Correspondent Name: ROBERT D. SHEREDA

Address Line 1: 2723 SOUTH STATE STREET

Address Line 2: SUITE 150

Address Line 4: ANN ARBOR, MICHIGAN 48104-6188

ATTORNEY DOCKET NUMBER:	16711-102
NAME OF SUBMITTER: ROBERT D. SHEREDA, REG. NO. 72408	
SIGNATURE:	/Robert D. Shereda/
DATE SIGNED:	01/03/2020

Total Attachments: 40
source=16711-102_Assmt_Inventors_to_NIBR#page1.tif
source=16711-102_Assmt_Inventors_to_NIBR#page2.tif
source=16711-102_Assmt_Inventors_to_NIBR#page3.tif
source=16711-102_Assmt_Inventors_to_NIBR#page4.tif
source=16711-102_Assmt_Inventors_to_NIBR#page5.tif
source=16711-102_Assmt_Inventors_to_NIBR#page6.tif
source=16711-102_Assmt_Inventors_to_NIBR#page7.tif
source=16711-102_Assmt_Inventors_to_NIBR#page8.tif
source=16711-102_Assmt_Inventors_to_NIBR#page9.tif
source=16711-102_Assmt_Inventors_to_NIBR#page10.tif
source=16711-102_Assmt_Inventors_to_NIBR#page11.tif
source=16711-102_Assmt_Inventors_to_NIBR#page12.tif
source=16711-102_Assmt_Inventors_to_NIBR#page13.tif
source=16711-102_Assmt_Inventors_to_NIBR#page14.tif
source=16711-102_Assmt_Inventors_to_NIBR#page15.tif
source=16711-102_Assmt_Inventors_to_NIBR#page16.tif
source=16711-102_Assmt_Inventors_to_NIBR#page17.tif
source=16711-102_Assmt_Inventors_to_NIBR#page18.tif
source=16711-102_Assmt_Inventors_to_NIBR#page19.tif
source=16711-102_Assmt_Inventors_to_NIBR#page20.tif
source=16711-102_Assmt_Inventors_to_NIBR#page21.tif
source=16711-102_Assmt_Inventors_to_NIBR#page22.tif
source=16711-102_Assmt_Inventors_to_NIBR#page23.tif
source=16711-102_Assmt_Inventors_to_NIBR#page24.tif
source=16711-102_Assmt_Inventors_to_NIBR#page25.tif
source=16711-102_Assmt_Inventors_to_NIBR#page26.tif
source=16711-102_Assmt_Inventors_to_NIBR#page27.tif
source=16711-102_Assmt_Inventors_to_NIBR#page28.tif
source=16711-102_Assmt_Inventors_to_NIBR#page29.tif
source=16711-102_Assmt_Inventors_to_NIBR#page30.tif
source=16711-102_Assmt_Inventors_to_NIBR#page31.tif
source=16711-102_Assmt_Inventors_to_NIBR#page32.tif
source=16711-102_Assmt_Inventors_to_NIBR#page33.tif
source=16711-102_Assmt_Inventors_to_NIBR#page34.tif
source=16711-102_Assmt_Inventors_to_NIBR#page35.tif
source=16711-102_Assmt_Inventors_to_NIBR#page36.tif
source=16711-102_Assmt_Inventors_to_NIBR#page37.tif
source=16711-102_Assmt_Inventors_to_NIBR#page38.tif
source=16711-102_Assmt_Inventors_to_NIBR#page39.tif
source=16711-102_Assmt_Inventors_to_NIBR#page40.tif

This Assignment Agreement is entered into by and between:

Christopher BECKER	citizen of United States of	51 Harvard Road
	America	Stow, MA 01775
		United States of America
Xiaolin LI	citizen of China	19th Floor, Block D, Tsinghua
		Tongfang Hi-Tech Plaza, No.1
		Wang Zhuang Road, Haidian,
		Beijing
		China
Peichao LU	citizen of China	Novartis Institutes for BioMedical
		Research Inc.
		5300 Chiron Way
		Emeryville, CA 94608
		United States of America
Naomi Samadara	citizen of United States of	1 DNA Way, MS 50, South San
RAJAPAKSA	America	Francisco, CA 94080
		United States of America
David Charles TULLY	citizen of United States of	Novartis Institutes for Biomedical
	America	Research, Inc.
		5300 Chiron Way
		Emeryville, California 94608
		United States of America
Xiaojing Michael	citizen of United States of	3060 Chateau Way
WANG	America	Livermore, CA 94550
		United States of America
Qian ZHAO	citizen of China	681 St. Andrews Lane
		Louisville, CO 80027
		United States of America

(hereinafter "Inventor(s)"),

and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Ave, Cambridge, Massachusetts 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

# ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

and filed in the United States Patent and Trademark Office on September 12, 2019 and accorded Application Number 16/569,107;

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);
- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for

- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Execute	ed this day of, 2019
Christo	pher BECKER
Witness	i;
	Printed Name: City, State and Country:
Witness	
	Printed Name: City, State and Country:
Execute	d this 28th day of October, 2019
Xiaolin	ĹI
Witness	Exchang h' ph, D philadelphia, pA, U.A.  Printed Name: City, State and Country:
Witness	Feng Shi, Ph.D., Beijing, P.R. China Printed Name: City, State and Country: 12 1

Execute	ed this day of	, 2019
Peichao	LU	
Witness		
	Printed Name:	
	City, State and Country:	
Witness	<b>.</b>	
W IELIODE	Printed Name:	
	City, State and Country:	
	•	
Execute	ed this day of	, 2019
NY	O	<del>.</del>
iyaoiiii i	Samadara RAJAPAKSA	
Witness	::	
	Printed Name:	
	City, State and Country:	
33.7%		
Witness	: Printed Name:	
	City, State and Country:	

Executed this	day of	, 2019
David Charles TU	JLLY	
Witness:		
Printed	Name:	
	ate and Country:	
Witness:		
Printed 1	Name:	
City, Sta	ate and Country:	
Executed this	day of	, 2019
Xiaojing Michael	WANG	
Witness:		
Printed 1	Name:	
City, Sta	te and Country:	
Witness:		
Printed 1		
City, Sta	te and Country:	

Executed this day of		, 2019
Qian Z	<b>УНАО</b>	
Witnes	Printed Name: City, State and Country:	
Witnes	Printed Name: City, State and Country:	

Executed this May of Otto, 2019 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. BY Printed Name: **Authorized Signatory** 

Witness:

Printed Name: VIVIAN

City, State and Country:

5308 Chiron Way Emeryville, CA 94608

Witness:

City, State and Country:

5300 Chiron Way Emeryvilla, CA 94608

This Assignment Agreement is entered into by and between:

Christopher BECKER	citizen of United States of	51 Harvard Road
	America	Stow, MA 01775
		United States of America
Xiaolin LI	citizen of China	19th Floor, Block D, Tsinghua
		Tongfang Hi-Tech Plaza, No.1
		Wang Zhuang Road, Haidian,
		Beijing
		China
Peichao LU	citizen of China	Novartis Institutes for BioMedical
		Research Inc.
		5300 Chiron Way
		Emeryville, CA 94608
		United States of America
Naomi Samadara	citizen of United States of	1 DNA Way, MS 50, South San
RAJAPAKSA	America	Francisco, CA 94080
		United States of America
David Charles TULLY	citizen of United States of	Novartis Institutes for Biomedical
	America	Research, Inc.
		5300 Chiron Way
		Emeryville, California 94608
		United States of America
Xiaojing Michael	citizen of United States of	3060 Chateau Way
WANG	America	Livermore, CA 94550
		United States of America
Qian ZHAO	citizen of China	681 St. Andrews Lane
		Louisville, CO 80027
		United States of America

(hereinafter "Inventor(s)"),

and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Ave, Cambridge, Massachusetts 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

- If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to
- (1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

# ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

and filed in the United States Patent and Trademark Office on <u>September 12, 2019</u> and accorded Application Number <u>16/569,107</u>;

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);
- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for

- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Execute	ed this day of	, 2019
Christo	pher BECKER	
Witness		
	Printed Name:	
	City, State and Country:	
Witness	s:	
	Printed Name:	
	City, State and Country:	
Execute	ed this day of	, 2019
Xiaolin	LI	
Witness		
	Printed Name:	
	City, State and Country:	
Witness		
71.161.000	: Printed Name:	
	City, State and Country:	

Executed	d this day of	, 2019
Peichao	LU	
Witness:		
	Printed Name:	
	City, State and Country:	
Witness:		
	Printed Name:	
	City, State and Country:	
Executed	this day of	, 2019
Naomi S	amadara RAJAPAKSA	<del></del> -
Witness:		
	Printed Name:	
	City, State and Country:	
Witness:		
	Printed Name:	
	City, State and Country:	

Execute	d this day of	, 2019
D .10	1 1 THE LAND	
David C	harles TULLY	
Witness		
	Printed Name:	
	City, State and Country:	
Witness:	D. L. INT	
	Printed Name:	
	City, State and Country:	
Executed	this day of	, 2019
 Xiaojing	Michael WANG	
Witness:		
	Printed Name:	
	City, State and Country:	
Witness:	1997-1	
	Printed Name:	
	City, State and Country:	

Executed	I this $25\%$ day of $2019$
7	<u> </u>
Qian ZH	ÃO
Witness:	
	Printed Name: Enclosed States and Country: Bookster, CO USA
Witness:	484-
	Printed Name: Appara Herwith
	City, State and Country: Souther, CO a USA

This Assignment Agreement is entered into by and between:

Christopher BECKER	citizen of United States of	51 Harvard Road	
	America	Stow, MA 01775	
		United States of America	
Xiaolin LI	citizen of China	19th Floor, Block D, Tsinghua	
		Tongfang Hi-Tech Plaza, No.1	
		Wang Zhuang Road, Haidian,	
		Beijing	
		China	
Peichao LU	citizen of China	Novartis Institutes for BioMedical	
		Research Inc.	
		5300 Chiron Way	
		Emeryville, CA 94608	
		United States of America	
Naomi Samadara	citizen of United States of	1 DNA Way, MS 50, South San	
RAJAPAKSA	America	Francisco, CA 94080	
		United States of America	
David Charles TULLY	citizen of United States of	Novartis Institutes for Biomedical	
	America	Research, Inc.	
		5300 Chiron Way	
		Emeryville, California 94608	
		United States of America	
Xiaojing Michael	citizen of United States of	3060 Chateau Way	
WANG	America	Livermore, CA 94550	
		United States of America	
Qian ZHAO	citizen of China	681 St. Andrews Lane	
		Louisville, CO 80027	
		United States of America	

(hereinafter "Inventor(s)"),

and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH**, **INC.**, 250 Massachusetts Ave, Cambridge, Massachusetts 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

## ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

and filed in the United States Patent and Trademark Office on <u>September 12, 2019</u> and accorded Application Number <u>16/569,107</u>;

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);
- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for

- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed	l this <u>24</u>	day of Oct	sper	_, 2019
Christon	toch,	day of <u>Och</u> Andi	7	
Спизор	noi Discissi	~		
Witness:	Printed Nam City, State a	ne: Kristen and Country:	Terran Framingh	OVA UMAH USA
Witness:		1 1 - KAU 10: JB11N		$\wedge$
		ind Country:		
Executed	l this	day of		_, 2019
Xiaolin I	I			<del></del>
Witness:	Printed Nam City, State a			
Witness:	Printed Nam	ne:		
		nd Country:		

Executed this
the state of the s
Peichao LU
Witness:  Printed Name: VANESA AAS 5300 Chiron Way City, State and Country: Emeryville, CA 94608
Witness:  Printed Name: City, State and Country:  Sito Chison Wey Energyills, CA 94608
Executed this day of, 2019
Naomi Samadara RAJAPAKSA
Witness: Printed Name: City, State and Country:
Witness:
Printed Name: City. State and Country:

<b>3</b> 25	10: 28 1 October 2010
Execute	d tms day of
	d this 28 day of Oldober, 2019
David C	harles TULLY
	Care de la
Witness	
	Printed Name: Manage Robinson
	City, State and Country: Con Environ, CA
Witness	Printed Name: 2500 0500 City, State and Country: Executive, CF
	City State and Comments
	City, State and Country: Cart Quantum
Executed	d this day of, 2019
Vicalina	Michael WANG
Viaolinā	whender warve
Witness	Printed Name:
	City, State and Country:
XX I* I	
Witness:	D.J. c. J.N.
	Printed Name: City State and Country:
	A HV ADDE MICH CHRISTO

Execut	ted this day of	, 2019
Qian Z	ZHAO	
Witnes	ss: Printed Name: City, State and Country:	
Witnes	Printed Name: City, State and Country:	

Executed this Aay of ) ( , 2019	
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.	
BY	
Printed Name: Y Na Land Lives Authorized Signatory	
Witness:	
Printed Name: 1/1/1/1/1/ / Ray 5300 Chiros Way City, State and Country: 5300 Chiros Way Emeryvilla, CA 94608	
Witness:	
Printed Name: City, State and Country:  5300 Chines Way Emeryville, CA SW	čna

This Assignment Agreement is entered into by and between:

citizen of United States of	51 Harvard Road	
America	Stow, MA 01775	
	United States of America	
citizen of China	19th Floor, Block D, Tsinghua	
	Tongfang Hi-Tech Plaza, No.1	
	Wang Zhuang Road, Haidian,	
	Beijing	
	China	
citizen of China	Novartis Institutes for BioMedical	
	Research Inc.	
	5300 Chiron Way	
	Emeryville, CA 94608	
	United States of America	
citizen of United States of	1 DNA Way, MS 50, South San	
America	Francisco, CA 94080	
	United States of America	
citizen of United States of	Novartis Institutes for Biomedical	
America	Research, Inc.	
	5300 Chiron Way	
	Emeryville, California 94608	
	United States of America	
citizen of United States of	3060 Chateau Way	
America	Livermore, CA 94550	
	United States of America	
citizen of China	681 St. Andrews Lane	
	Louisville, CO 80027	
	United States of America	
	citizen of China  citizen of China  citizen of United States of America  citizen of United States of America  citizen of United States of America	

(hereinafter "Inventor(s)"),

and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Ave, Cambridge, Massachusetts 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

#### ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

and filed in the United States Patent and Trademark Office on <u>September 12, 2019</u> and accorded Application Number <u>16/569,107</u>;

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);
- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for

- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Execute	d this day of	, 2019
Christop	oher BECKER	
Witness	:	
7,	Printed Name:	
	City, State and Country:	
Witness	E	
	Printed Name:	
	City, State and Country:	
Execute	d this day of	, 2019
Xiaolin	LÏ	
Witness	:	
	Printed Name:	
	City, State and Country:	
Witness		
	Printed Name:	
	City, State and Country:	

Execute	d this day of	, 2019
Peichao	LU	
Witness	:	
	Printed Name:	
	City, State and Country:	
Witness:	75.1.127	
	Printed Name:	
	City, State and Country:	
Executed	this day of	, 2019
Naomi S	amadara RAJAPAKSA	
Witness:		
	Printed Name:	
	City, State and Country:	
Witness:		
	Printed Name:	
	City, State and Country:	

Execute	d this	day of	, 2019
David C	harles TULL	Y	
Witness			
	Printed Nam		
	City, State a	nd Country:	
Witness			
	Printed Nam	e:	
	City, State ar	nd Country:	
Execute	1 this 29	day of Oct	ober, 2019
	75	wo	
Xiaojing	Michael WA	ŊĠ	
	and	2	_
Witness:	1/b///	/h~	
0	Printed Nam	e: PAULINE	PEIRONG GU
	City, State ar	nd Country: D	Lhn, CA, USA
Witness:	1/1	72c F.D.	= eger)
	Printed Name	e: Masse	Fitzgerad
	City, State ar	nd Country:	racy, 1A, USA
			7, JUNE

Execute	d this day of	, 2019
Qian ZI	IAO	
Witness	:	
Witness	Printed Name: City, State and Country:	

Executed th	nis <u>May of CC</u> , 2019	
NOVARTI	S INSTITUTES FOR BIOMEDICAL RE	SEARCH, INC.
	ied Name: The Norized Signatory	<b>&gt;</b>
Witness:	Printed Name: VIVIAN TRAN City, State and Country:	5300 Chiron Way
Witness:	Printed Name: City, State and Country:	Emeryvilla, CA 94608

5300 Chiron Way Emcryville, CA 94608

This Assignment Agreement is entered into by and between:

Christopher BECKER	citizen of United States of	51 Harvard Road
	America	Stow, MA 01775
		United States of America
Xiaolin LI	citizen of China	19th Floor, Block D, Tsinghua
		Tongfang Hi-Tech Plaza, No.1
		Wang Zhuang Road, Haidian,
		Beijing
		China
Peichao LU	citizen of China	Novartis Institutes for BioMedical
		Research Inc.
		5300 Chiron Way
		Emeryville, CA 94608
		United States of America
Naomi Samadara	citizen of United States of	1 DNA Way, MS 50, South San
RAJAPAKSA	America	Francisco, CA 94080
		United States of America
David Charles TULLY	citizen of United States of	Novartis Institutes for Biomedical
	America	Research, Inc.
		5300 Chiron Way
		Emeryville, California 94608
		United States of America
Xiaojing Michael	citizen of United States of	3060 Chateau Way
WANG	America	Livermore, CA 94550
		United States of America
Qian ZHAO	citizen of China	681 St. Andrews Lane
		Louisville, CO 80027
		United States of America

(hereinafter "Inventor(s)"),

and **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH**, **INC.**, 250 Massachusetts Ave, Cambridge, Massachusetts 02139, USA, a company organized under the laws of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

# ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

and filed in the United States Patent and Trademark Office on <u>September 12, 2019</u> and accorded Application Number <u>16/569,107</u>;

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);
- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for

- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed	l this da	y of	, 2019
Christop	her BECKER		***************************************
Witness:			
	Printed Name:		
	City, State and	Country:	
Witness:			
	Printed Name:		
	City, State and	Country:	
Executed	this da	y of	, 2019
Xiaolin l			and the control of th
Witness:			
	Printed Name:	•	
	City, State and	Country:	
Witness:			
	Printed Name:		
	City, State and	Country:	

Execute	d this day of	, 2019
25.2.3	7.77	
Peichao	LU	
Witness	•	
	Printed Name:	<del></del>
	City, State and Country:	
Witness		
	Printed Name:	
	City, State and Country:	
Execute	d this <u>24</u> day of <u>0ch pe/</u>	_, 2019
Naomi Š	iamadara RAJAPAKSA	in his his his his high
Witness:		
	Printed Name: King Hoard	
	City, State and Country: Bookeley	,ca,con
Witness:		
	Printed Name: Fry Crawfort	***************************************
	City, State and Country: Jan Made.	och waa

Executed	l this	_ day of	, 2019
			***************************************
David C	harles TULL	ĽΥ	
Witness:		ne:	
	•		
	City, State a	and Country:	
Witness:			
	Printed Nan	:	
	City, State a	and Country:	
Executed	l this	day of	, 2019
Briocaro	t tilly		
	Michael W	ANG	
Alaojing	Milonact 44.2	3110	
Witness:			
withess:	Printed Nan	20'	
		and Country:	
	City, State 2	ina Country.	
IT 7" 4			
Witness:	Printed Nan		
	City, State a	and Country:	

	day of	, 2019	
VO		·····	
	•		•
Printed N	Jame:		
	Printed N City, Sta	Printed Name: City, State and Country: Printed Name: City, State and Country:	Printed Name: City, State and Country: Printed Name:

Executed this	<u>UN</u> day of	Dec_	, 2019	
NOVARTIS	INSTITUTES	FOR BIOMEI	DICAL RESEARC	H, INC.

Witness:

BY

Printed Name:

Authorized Signatory

Printed Name: Whylan City, State and Country:

5300 Chiron Way Emeryville, CA 94608

Witness:

Printed Name:

City, State and Country:

5300 Chiron Way Emeryvilla, CA 94608

THAN)